Actively Recruiting
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2024-05-07
55
Participants Needed
2
Research Sites
144 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multi-center, Single-arm Phase II study to evaluate the clinical efficacy and safety of Consolidation HLX10 (Serplulimab) Following Hypofractionated Radiotherapy With Concurrent Chemotherapy for Patients With Limited Stage Small Cell Lung Cancer
CONDITIONS
Official Title
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years with ECOG performance status 0-1
- Histologically or cytologically confirmed small cell lung cancer
- Limited stage disease confined to one side of the chest including specified lymph nodes
- No confirmed malignant pleural effusion thicker than 1 cm on chest CT unless cytologically confirmed
- No prior anti-tumor treatment history
- Expected survival of at least 3 months
- No serious medical diseases or major organ dysfunction affecting blood, liver, kidney, heart, or lung function
You will not qualify if you...
- Mixed small cell lung cancer diagnosis
- Patients suitable for surgery (unless they refuse surgery)
- Previous systemic anti-tumor treatments for small cell lung cancer
- Other active cancers within 5 years or concurrent malignancies
- Known severe allergy to any monoclonal antibody
- Known anaphylaxis to carboplatin, cisplatin, or etoposide
- Any other factors that may cause early study discontinuation as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Jiamusi Cancer Hospital
Jiamusi, Heilongjiang, China, 154007
Actively Recruiting
2
Shanxi Province Cancer Hospital
Taiyuan, Shanxi, China, 030013
Actively Recruiting
Research Team
N
Nan Bi, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here